Local delivery of hrBMP4 as an anticancer therapy in patients with recurrent glioblastoma: a first-in-human phase 1 dose escalation trial

BACKGROUND: This Phase 1 study evaluates the intra- and peritumoral administration by convection enhanced delivery (CED) of human recombinant Bone Morphogenetic Protein 4 (hrBMP4) – an inhibitory regulator of cancer stem cells (CSCs) – in recurrent glioblastoma. METHODS: In a 3 + 3 dose escalation d...

Descripción completa

Detalles Bibliográficos
Autores principales: Bos, Eelke M., Binda, Elena, Verploegh, Iris S.C., Wembacher, Eva, Hoefnagel, Daphna, Balvers, Rutger K., Korporaal, Anne L., Conidi, Andrea, Warnert, Esther A. H., Trivieri, Nadia, Visioli, Alberto, Zaccarini, Paola, Caiola, Laura, van Wijck, Rogier, van der Spek, Peter, Huylebroeck, Danny, Leenstra, Sieger, Lamfers, Martine L.M., Ram, Zvi, Westphal, Manfred, Noske, David, Legnani, Federico, DiMeco, Francesco, Vescovi, Angelo Luigi, Dirven, Clemens M.F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413694/
https://www.ncbi.nlm.nih.gov/pubmed/37563568
http://dx.doi.org/10.1186/s12943-023-01835-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413694/
https://www.ncbi.nlm.nih.gov/pubmed/37563568
http://dx.doi.org/10.1186/s12943-023-01835-6

Ejemplares similares